BCRX — BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc (BCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Jon P. Stonehouse, based in 4505 Emperor Boulevard, Durham, NC, United States, 27703, with about 580 employees. BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Net income was $12.9M. BCRX currently screens at market cap $1.83B.

Use this BCRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BCRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BCRX SEC filings page. Lician reads the product cache first so this HTML stays unique to BioCryst Pharmaceuticals Inc even when a live quote feed is slow.